WHO Expert Committee on Drug Dependence. Thirty-second report.

Controlling Dependence-Producing Drugs

This report summarizes the recommendations of the World Health Organization (WHO) Expert Committee on Drug Dependence. The committee reviews information on dependence-producing drugs to assess the need for international control. The report highlights the committee's evaluation of six substances, including 4-bromo-2,5-dimethoxyphenethylamine (2C-B), 4-methylthioamphetamine (4-MTA), gamma-hydroxybutyric acid (GHB), N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MDBD), diazepam, and zolpidem. Four of these substances (2C-B, 4-MTA, GHB, and zolpidem) were recommended for international control, reflecting the committee's commitment to safeguarding public health and mitigating the risks associated with dependence-producing drugs.

Guiding International Drug Control Policies

This report plays a crucial role in shaping international drug control policies. The committee's recommendations provide guidance to governments and health organizations worldwide in their efforts to manage the risks associated with dependence-producing substances. This report underscores the importance of a global approach to addressing the complex challenges posed by drug dependence.

Protecting Public Health

This report emphasizes the importance of international collaboration in protecting public health from the harms associated with dependence-producing drugs. The committee's work reflects a global commitment to addressing this complex issue and promoting the health and well-being of individuals and communities around the world.

Dr.Camel's Conclusion

This report is a reminder that drug dependence is a global issue requiring a coordinated response. The committee's work reflects a commitment to evidence-based decision-making and a focus on protecting public health. This report serves as a beacon of hope, highlighting the potential for collaboration and action to mitigate the harms associated with drug dependence.